SRNE News and Press, Sorrento Therapeutics Inc. From 11/16/21

When big money bets against a stock through short positions, that’s vital intelligence for your own investment decisions. Equally important is whether or not the company has the fundamentals to turn things around. Unfortunately, some very popular stocks have attracted worri...

Sorrento Therapeutics released its Q3-2021 results. COVISTIX received "CE" Mark and approval for marketing in Belgium. Brazilian authority approved the use of COVISTIX in the Country. For further details see: Sorrento Therapeutics: COVISTIX Will Support The Growth

SAN DIEGO and MEXICO CITY, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and the World Boxing Council (“WBC”) announced today that Sorrento’s COVI-STIX COVID-19 Virus Rapid Antigen Detection Test (“COVI-STI...

Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor that irreversibly targets mutant forms of EGFR and Bruton’s tyrosine kinase (BTK) in advanced NSCLC patients resistant to first-line EGFR kinase inhibitor therapies. In this pivotal st...

Palm Beach, FL – November 9, 2021 – FinancialNewsMedia.com News Commentary – The increasing outbreak of covid-19 is increasing the demand for coronavirus vaccines or therapies, which will result in the expansion of the COVID-19 therapeutics market during the...

SAN DIEGO, Nov. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the California Competes Tax Credit Committee has approved the California Competes Tax Credit Allocation Agreement (the “Agreement”) between Sorrento and the...

Sorrento Therapeutics (SRNE +2.3%) announced that the national agency for approval of food, cosmetics, and medical devices (ANVISA) in Brazil has authorized COVISTIX, a rapid diagnostic test for the detection of SARS-CoV-2 antigen. With the ANVISA approval for the test, COVISTIX will now be a...

COVISTIX now approved for point of care use in symptomatic patients by ANVISA (national agency for approval of food, cosmetics, and medical devices) in Brazil. Commercialization in progress with distribution agreement locally established and initial purchase orders pending process...

Are These Top Biotech Stocks Worth Investing In This Month? Biotech stocks have and continue to make waves across the stock market today . For the most part, this would be due to the overwhelming focus on the industry amidst the pandemic. In fact, new data from Johns Hopkins Uni...

Sorrento Therapeutics (NASDAQ:SRNE) license partner China Oncology Focus has submitted a new drug application for socazolimab for the greater China territory to treat recurrent or metastatic cervical cancer. China Oncology Focus is an affiliate of Lee's Pharmaceutical Holdings....